23 May 2013
Keywords: macusight, initiates, 30-patient, sirolimus, trial, usa-based, developer
Article | 06 November 2006
MacuSight, a USA-based developer of therapeutics for the treatment of severe ocular conditions, has initiated a Phase I study of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 November 2006
22 May 2013
© 2013 thepharmaletter.com